Dr. Karin Denton:

I will refer to the key part which is mentioned on page 90. The reason it may come across that I am being somewhat indecisive is we do not have exact definitions of which patient groups were involved. If one looks at the first few paragraphs of section 8.4, one will see we found a partial presentation of the audit in 2015. It talks about review outcomes in 190 cases that were then known. It runs through the number of women involved and how it was decided whether it had impacted on their management. What we do not know is how a proportion of those 190 women relate to the group of 221 women. This is a matter about which I have been very concerned, which is why I have been trying to get more information this week, but it is still incomplete. I have not been assured, but it may be that there was no delay factored in in the group of 221 women, but it may also be that there was. We have to be aware of this. There may, in fact, be other women whose samples were altered on review who have not been included in the group of 221 women, plus the cases that were included in the cancer registry group who we know have not been included.